Advertisement

Psychodysleptica

  • Thomas Geschwinde

Zusammenfassung

Vorbemerkung: Die Zusammenfassung psychotroper Stoffe der verschiedensten chemischen Struktur und Anwendungsformen unter Oberbegriffen erfolgt in diesem Buch in erster Linie im Hinblick auf vergleichbare durch sie ausgelöste psychische Wirkungen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Abel EL (1971) Marihuana and memory: acquisition or retrieval ? Science 173:1038–1040 Abel EL ( 1976 ) The scientific study of marihuana. Hall, ChikagoGoogle Scholar
  2. Abelson PH (1968) LSD and marihuana. Science 159: 89–97Google Scholar
  3. Aberle D (1966) The Peyote religion among the Navaho. Aldine, ChikagoGoogle Scholar
  4. Ablon SL, Goodwin FK (1974) High frequency of dysphoric reactions to tetrahydrocannabinol among depressed patients. Am J Psychiatry 131: 448–453Google Scholar
  5. Abood LG, Biel JH (1962) Anticholinerge Psychotomimetica. Int Rev Neurobiol 4: 217–273CrossRefGoogle Scholar
  6. Adams AJ et al. (1975) Alcohol and marihuana effects on static visual acuity. Am J Ophthalmol 52: 729–735Google Scholar
  7. Agurell S et al. (1971) Metabolism of 7-hydroxy-delta-1-(16)-THC and CBN. Acta Pharm Suec 8Google Scholar
  8. Agurell S, Gustafson B, Holmstedt B (1973) Quantitation of Atetrahydrocannabinol in plasma from cannabis smokers. J Pharm Pharmacol 25: 448–554CrossRefGoogle Scholar
  9. Agurell S, Dewey WL, Willette RE (eds) (1984) The cannabinoids: chemical, pharmacologic and therapeutic aspects. Academic Press, New YorkGoogle Scholar
  10. Akinloye BA, Court WE (1981) The alkaloids of Rauwolfia volsinii. J Etnopharmacol 4: 99–109CrossRefGoogle Scholar
  11. Algeier-Föll R (1991) Cannabis und Verkehrstauglichkeit (Literaturüberblick). Zentralbl Rechtsmed 35: 614–623Google Scholar
  12. Alpert R (1969) Psychedelics and sexual behavior. J Sex Res 5: 50–54CrossRefGoogle Scholar
  13. Alt A, Reinhardt G (1996) Speiseöle auf Hanfbasis und ihr Einfluß auf die Ergebnisse von Urin-und Blutanalysen. Blutalkohol 33: 347–356Google Scholar
  14. Alt A, Reinhardt G (1997) Nahrungsmittel auf Hanfbasis und deren forensische Bedeutung. Blutalkohol 34: 286–293Google Scholar
  15. Amendt G (1974) Haschisch und Sexualität. Enke, StuttgartGoogle Scholar
  16. Anderson EF (1969) The biogeography, ecology, and taxonomy of lophophora (cactacea). Brittonia 21 /4: 229–310CrossRefGoogle Scholar
  17. Andersson PG (1975) Ergotamine headache. Headache 15: 118–121CrossRefGoogle Scholar
  18. Andréasson S, Engström A, Allebeck P, Rydberg U (1988) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 11: 1483–1486Google Scholar
  19. Andrews G, Vinkenoog S (eds) (1968) The book of grass. Grove, New York Angst J (1970) Halluzinogen-Abusus. Schweiz Med Wochenschr 100: 710–715Google Scholar
  20. Angst J, Dittrich A, Woggon B (1972) Psychologische und klinische Aspekte des Cannabismißbrauchs. Z Allgemeinmed 48: 94–99Google Scholar
  21. Bachmann EW, Hoffmann AA, Waser PG (1979) Identification of A9-tetrahydrocannabinol in human plasma by gas chromatography. J Chrom 178: 320–323CrossRefGoogle Scholar
  22. Bailey DN (1979) Phericyclidine abuse. Am Clin Pathol 72: 759Google Scholar
  23. Baker AA, Lukas EG (1969) Some hospital admissions associated with cannabis. Lancet 1: 148–160CrossRefGoogle Scholar
  24. Balster RL, Chait LD (1976) The behavioral pharmakology of phencyclidine. Clin Toxicol 9 /4: 573–578CrossRefGoogle Scholar
  25. Barnes C, Fried PA (1974) Tolerance to delta-9-THC in adult rats with differential delta-9THC exposure with immature or during early adulthood. Psychopharmacology (Berlin) 34: 181–190CrossRefGoogle Scholar
  26. Battegay R, Bäumler J, Gnirss F, Ladewig D (1969) Zur Drogenabhängigkeit vom Typ Cannabis ( Haschisch, Marihuana). Schweiz Med Wochenschr 99: 965–971Google Scholar
  27. Battersby AR (1963) Recent researches on indole alkaloids. Pure Appl Chem 6: 471–488CrossRefGoogle Scholar
  28. Bauer W (Hrsg) (1980) Fliegenpilz - Fleisch der Götter. Schamanistische Ekstasekulte in Europa. Trikont, München.Google Scholar
  29. Baumgartner AM, Jones PF, Black CT (1981) Detection of phencyclidine in hair. J Forensic Sci 26: 576–581Google Scholar
  30. Baumgartner WA (1986) Analysis of tetrahydrocannabinol (THC) in hair. US Navy Rehabilitation Center Study, Final Report, pp 1–16Google Scholar
  31. Beaubrun MH, Knight F (1973) Psychiatric assessment of 30 chronic users of cannabis and 30 matched controls. Am J Psychiatry 130: 309–311Google Scholar
  32. Bogusz M, Schmidt G (1990) Forensisch-toxikologische Aspekte des Cannabis-Missbrauchs. Zbl Rechtsmed 33: 383–398Google Scholar
  33. Behr H-G (oJ) Haschisch-Kochbuch. Volksverlag, LindenGoogle Scholar
  34. Behr H-G (1982) Von Hanf ist die Rede. Sphinx, BaselGoogle Scholar
  35. Benecke M (1997) TECHNO–Eine verwirrende Partykultur. Kriminalistik 7: 475–479Google Scholar
  36. Benitez F (1968) En la tierra màgica del peyote. Biblioteca Era, Serie Popular, MexikoGoogle Scholar
  37. Berghaus G, Krüger H-P (Hrsg) (1998) Cannabis im Straßenverkehr. Gustav-Fischer, Stuttgart, Jena, Lübeck, UlmGoogle Scholar
  38. Berhardson G, Gunne LM (1972) 46 cases of psychoses in cannabis abusers. Int J Addict 7: 9–16Google Scholar
  39. Beringer K (1927) Der Meskalinrausch. Springer, Berlin (Neudruck 1969 )Google Scholar
  40. Beringer K (1932) Zur Klinik des Haschischrausches. Nervenarzt 5: 30–41Google Scholar
  41. Berkefeldt K, Löhrer F (1998) Biogene Drogen. Kriminalistik 8–9: 563–566Google Scholar
  42. Betz P, Janzen J, Roider G et al (1991) Psychopathologische Befunde nach Aufnahme von Inhaltsstoffen heimischer Nachtschattengewächse. Archiv f Kriminol 188: 175–182Google Scholar
  43. Bialos DS (1970) Adverse marijuana reactions: A critical examination of the literature with selected cas material. Am J Psychiatry 127: 819–823Google Scholar
  44. Binder MA (1981) Haschisch und Marihuana–was der Arzt über Cannabinoide wissen sollte. Dtsch Ärztebl 78: 117–120Google Scholar
  45. Bischoff WH (1966) The exstasy drugs. Univ Circle Press, Delray BeachGoogle Scholar
  46. Blaine JD, Meacham MP, Janowsky DS, Schoor M, Bozetti LP (1976) Pharmacology of marijuana. Raven, New YorkGoogle Scholar
  47. Blevins D, Regan JD (1976) Delta-9-THC. Effect an macromolecular synthesis in human and other mammalian cells. In: Nahas GG, Paton WOM, Idänpää-Heikkilä JF (eds) Marihuana: Chemistry, biochemistry, and cellular effects. Springer, New York, pp 3268Google Scholar
  48. Boettcher C (1866) Über die Anwendung des indischen Hanfes in der Psychiatrie. Berl Klin Wochenschr 3Google Scholar
  49. Bonnie RJ, Whitebread CH (1978) The marihuana conviction. Univ Press of Virginia, CharlottesvilleGoogle Scholar
  50. Borg J, Gershon S, Alpert M (1975) Dose effects of smoked marihuana on human cognitive and motor function. Psychopharmacologia 42: 211–218CrossRefGoogle Scholar
  51. Boroffca A (1978) Cannabis und Psychiatrie. Suchtgefahren 24: 28–37Google Scholar
  52. Bost RO (1988) 3,4-Methylendioxymethamphetamine (MDMA) and other Amphetamine Derivats. J Forensic Sci 33/2:576–587Google Scholar
  53. Bové FJ (1970) The story of Ergot. Karger, BaselGoogle Scholar
  54. Bowman M, Pihl R (1973) Cannabis: Psychiological effects of chronic heavy use. Psycho-pharmacology (Berlin) 29: 159–170Google Scholar
  55. Bram S, Bracet P (1976) Inhibition of proliferation and differentation of D. dicoideum amoebae by THC and cannabinol. In: Nahas GG, Paton WOM, Idänpää-Heikkilä JF (eds) Marihuna: Chemistry, biochemistry, and cellular effects. Springer, New York, pp 116–138Google Scholar
  56. Bratzke H, Klug E (1985) Gewaltdelikte und LSD-Rausch. Beitr gerichtl Med 43: 179–186Google Scholar
  57. Braude MC, Szara S (eds) (1976) Pharmacology of marihuana. Raven, New YorkGoogle Scholar
  58. Brawley P et al. (1972) Pharmacology of hallucinogens. Pharmacol Rev 24Google Scholar
  59. Bremkamp S (1980) PCP: Learning to like a dangerous drug. J Psychedelic Drugs 12 /2: 171–172CrossRefGoogle Scholar
  60. Brickenstein R (1971) Gefahren der Cannabisdrogen für Heranwachsende. Z Allgemeinmed 47: 846–851Google Scholar
  61. Bromberg W (1934) Marihuana intoxication. Am J Psychiatry 91: 303–340Google Scholar
  62. Bromberger A, Goerke R, Weinmann W (1999) Bestimmungsgrenzen für den Nachweis von Cannabinoiden im Serum. Rechtsmed 9: 131–137CrossRefGoogle Scholar
  63. Bron B (1979) Psychopathologisches Erscheinungsbild und klinische Bedeutung des Horror-Trips. Suchtgefahren 25 /4: 167–176Google Scholar
  64. Bron B (1987) Drogeninduzierte Intoxikationen und Psychosen. Fortschr Med 4:73–76 und 5: 94–96Google Scholar
  65. Brown FC (1972) Halluzinogenic drugs. Thomas, Springfield/IlGoogle Scholar
  66. Brunner TF (1977) Marijuana in Ancient Greece and Rome ? J Psychedelic Drugs 9/3: 221225Google Scholar
  67. Bschor F (1950) Marihuana. Kriminalistik 4: 19–24Google Scholar
  68. Bull J (1971) Cerebral atrophy in young Cannabis smokers. Lancet 11: 1420–1448CrossRefGoogle Scholar
  69. Burns RS, Lerner SE (1976) Phencyclidine: An emerging drug problem. Clin Toxicol 9 /4: 473–475CrossRefGoogle Scholar
  70. Burns RS et al. (1978) Cause of PCP-related death. Clin Toxicol 12/4: 463 Burroughs W, Ginsberg A ( 1964 ) Auf der Suche nach Yagé. Limes, WiesbadenGoogle Scholar
  71. Burstein S, Kupfer D (1971) Hydroxylation of trans-delta-1-THC by hepatic microsomal oxygenase. Ann NY Acad Sci 191: 32–37CrossRefGoogle Scholar
  72. Butler JL, Gaines LS, Lenox JR (1976) Effects of marijuana expectation and suggestibility an cognitive functioning. Percept Mot Skills 42: 1059–1065CrossRefGoogle Scholar
  73. Bye RA jr (1979) Hallucinogenic plants of the tarahumara. J Ethnopharmacol 1: 23–48CrossRefGoogle Scholar
  74. Caldwelle DF et al. (1969) Auditory and visual threshold effects of marihuana in man. Percept Mot Skills 29: 755–759CrossRefGoogle Scholar
  75. Campbell AMG, Evans M, Thomson JLG, Williams MJ (1971) Cerebral atrophy in young cannabis smokers. Leancet 11: 1219–1224CrossRefGoogle Scholar
  76. Chait LD, Fischman MW, Schuster CR (1985) “Hangover” effects the morning after marijuana smoking. Drug Alcohol Depend 15:229–238Google Scholar
  77. Campbell AMG, Evans M, Thomson JLG, Williams MJ (1972) Cerebral atrophy in young cannabis smokers. Lancet 1:202 ffGoogle Scholar
  78. Carlin AS, Post RD (1971) Patterns of Drug Use Among Marihuna Smokers. Jama 218: 867–868CrossRefGoogle Scholar
  79. Carlin AS, Trupin EW (1977) The effect of long-term chronic marijuana use on neuropsychological functioning. Int J Addict 12: 36–48Google Scholar
  80. Carlin AS et al. (1972) Social facilitation of marihuana intoxication. J Abnorm Psychol 80: 132–140CrossRefGoogle Scholar
  81. Carlson KA (1979) PCP from the other side. J Psychedelic Drugs 11/3: 231–238 Cashman J ( 1968 ) LSD, die Wunderdroge. Ullstein, Frankfurt am MainGoogle Scholar
  82. Casswell M (1975) Cannabis and temporal desintegration on experienced and naive subjects. Science 179: 803–805CrossRefGoogle Scholar
  83. Casto D (1970) Marijuana and the assassins, an etymological investigation. Br J Addict 65: 219–225CrossRefGoogle Scholar
  84. Chatterjee A (1953) Rauwolfia alkaloids. Fortschr Chem Organ Naturst 10: 390–394Google Scholar
  85. Chavalampous KD, Walker KE, Kinross-Wright J (1966) Metabolic fate of mescaline in man. Psychopharm 9: 48–63CrossRefGoogle Scholar
  86. Cherniak L (1979) The great books of hashish. And/Or Press, BerkeleyGoogle Scholar
  87. Chiang C-W, Barnett G (1984) Marijuana effect and delta-9-tetrahydrocannabinol plasma level. Clin Pharmacol Ther 36: 234–238CrossRefGoogle Scholar
  88. Childers SR et al. (1994) Effects of Amandamide on Cannabinoid Receptors in Rat Brain Membrane. Biochem Pharmacol 47: 711–714CrossRefGoogle Scholar
  89. Chopra GS (1973) Studies an psycho-clinical aspects of long-term marihuana use in 124 cases. Int J Addict 8: 1015–1026Google Scholar
  90. Clark LD, Nakashima EN (1968) Experimental stufies of marihuana. Am J Psychiatry 125: 379–384Google Scholar
  91. Claussen U, Korte F (1966) Herkunft, Wirkung und Synthese der Inhaltsstoffe des Haschisch. Naturwissenschaften 21: 541–546Google Scholar
  92. Co BT, Goodwin DW, Gado M, Mikhael M, Hill SY (1977) Absence of cerebral atrophy in chronic cannabis users. Jama 237 /12: 1229–1230CrossRefGoogle Scholar
  93. Cohen S (1965) The beyond within - The LSD story. Atheneum, New YorkGoogle Scholar
  94. Cohen S (1966) A classification of LSD complications. Psychosomatics 7:182–186 Cohen S (1967) Psychotomimetics agents. Ann Rev Pharm 7: 301–318CrossRefGoogle Scholar
  95. Cohen S (1982) Cannabis and sex: Multifacted paradoxes. J Psychedelic Drugs 14/1–2: 55–58Google Scholar
  96. Colbach E (1971) Marijuana use by GI’s in Vietnam. Am J Psychiatry 128: 204–207Google Scholar
  97. Coleman JH, Tacker HL, Evans WE, Lemmi H, Britton EL (1976) Neurological manifestations of chronic marihuana intoxication. Part 1: Paresis of the fourth cranial nerve. Dis New Syst 37: 29–38Google Scholar
  98. Connor JE, Rejent TA (1981) EMIT cannabinoid assay: confirmation by RIA und GC/ MS. J Anal Tox 6: 168–173Google Scholar
  99. Consroe PF, Man DP (1973) Effects of 48- and A9-tetrahydrocannabinol on experimental induced seizures. Life Sci 13: 429–439CrossRefGoogle Scholar
  100. Cooper R (1978) A guide to British psilocybin mushrooms. Hassle Free PressGoogle Scholar
  101. Crawford WJ, Merritt JC (1979) Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm 17: 191–196Google Scholar
  102. DalCason TA (1989) The characterization of some 3,4-methylendioxyphenylisopropylamine (MDA) analogs. J Forensic Sci 34 /4: 928–961Google Scholar
  103. Daltrup T (1995) Bestimmung von Cannabinoiden. Toxichem u Krimtech 62: 21–27Google Scholar
  104. Daltrup T, Reudenbach G, Kimm K (1987) Cannabis und Alkohol im Straßenverkehr. Blutalkohol 24: 144–155Google Scholar
  105. Daltrup T, Käferstein H, Köhler H et al. (2000) Entscheidung zwischen einmaligem/gelegentlichem und regelmäßigem Cannabiskonsum. Blutalkohol 37: 39–47Google Scholar
  106. Dalterio S, Bartke A (1979) Perinatal exposure to cannabinoids alters male reproductive function in mice. Science 205: 1420–1422CrossRefGoogle Scholar
  107. Darley CF, Tinklenberg JR, Hollister TE et al. (1973) Marihuana and retrieval from short term memory. Psychopharmacol (Berlin) 29: 231–238CrossRefGoogle Scholar
  108. Daunderer M (1979) Therapie einer Atropa-belladonna-Vergiftung mit dem Antidot Physostigmin. Med Welt 30: 1743Google Scholar
  109. Davenport J (1966) Aphrodisiacs and love stimulants. Lyle Stuart, New YorkGoogle Scholar
  110. Demisch L, Kaczmarczyk P, Seiler N (1978) 3,4,5-Trimethoxybenzoic acid. A new mescaline metabolite in humans. Drug Met Disp 6: 507–509Google Scholar
  111. Devane WA et al. (1992) Isolation and Structure of a Brain Constituent that Binds to the Cannabinoid Receptor. Science 258: 1946–1947CrossRefGoogle Scholar
  112. Diaz JL (1979) Ethnopharmacology and Taxonomy of Mexican psychodysleptic plants. J Psychedelic Drugs 11/1–2: 71–101Google Scholar
  113. Dieckhöfer K, Goenchea S (1972) Zur Toxizität von Cannabis. 1. Mitteilung. Med Welt 23: 779–782Google Scholar
  114. Dittrich A, Hofmann A, Leuner M (Hrsg) (1994) Welten des Bewußtseins. Wissenschaft und Bildung, BerlinGoogle Scholar
  115. Domino EF (1981) Cannabinoids and the cholinergic system. J Clin Pharmacol Suppl 21: 149S - 255SCrossRefGoogle Scholar
  116. Don Castro III (1970) Marihuana and the assassins. Br J Addict 65: 35–39CrossRefGoogle Scholar
  117. Doorenbos NJ et al. (1971) Cultivation, extraction and analysis of cannabis. Ann NY Acad Sci 191: 90–95CrossRefGoogle Scholar
  118. Dornbusch RL, Abrams R, Fink M (1971) Marijuana, memory and perception. Am J Psychiatry 128: 194–197Google Scholar
  119. Dowling GP, McDonough ET, Bost RO (1987) “Eve” and “Ectasy”. A report of five deaths associated with the use of MDEA and MDMA. Jama 257 /12: 1615–1617CrossRefGoogle Scholar
  120. Eastman JW, Cohen SN (1975) Hypertensive Crisis and Death Associated with Phencyclidine Poisoning. Jama 231 /12: 1270–1271CrossRefGoogle Scholar
  121. Edery H, Soroko D, Kunberg W (1971) Structural requirements for cannabinoid activity. Ann NY Acad Sci 191: 139–145CrossRefGoogle Scholar
  122. Efron DH (1970) Psychotomimetic drugs. Raven. New YorkGoogle Scholar
  123. Efron D, Holmstedt B, Kline NS (eds) (1967) Ethnopharmacological search for psychoactive drugs. Public Health Sery Publ 1645: 211–216Google Scholar
  124. Eliade M (1956) Schamanismus und archaische Ekstasetechnik. Rascher, Zürich StuttgartGoogle Scholar
  125. Ellis GM Jr et al. (1985) Excretion patterns of cannabinoid metabolites after last use in a group of chronic Users. Clin Pharmacol Therap 38: 572–578CrossRefGoogle Scholar
  126. Enßlin HK et al. (1990) Trennung von MDA, MDE, MDMA: Verbindung von AMD-Technik und DC/IR-Koppelung. Toxichem/Krimtech 6 /57: 164–168Google Scholar
  127. Estrada A (1980) Maria Sabina. Botin der heiligen Pilze. Trikont, MünchenGoogle Scholar
  128. Eugster CH (1968) Wirkstoffe aus dem Fliegenpilz. Naturwissenschaften 55: 305–313CrossRefGoogle Scholar
  129. Farfel GM et al. (1995) Role of hypothermia in the mechanism of protection against serotonergic toxicity. J Pharmacol Exp Ther 272/2,1: 860–867, 11: 868–875Google Scholar
  130. Farnsworth NR (1968) Halluzinogenic plants. Science 162: 96–105CrossRefGoogle Scholar
  131. Feldman HW et al. (eds)(1979) Angel dust: An ethnographic study of PCP users. Lexington Books, Lexington/MAGoogle Scholar
  132. Feuerlein W (Hrsg.) (1980) Cannabis heute. Bestandsaufnahme zum Haschischproblem. Akademische Verlagsgesellschaft, WiesbadenGoogle Scholar
  133. Fink DJ, Ashworth B, Brewer C (1972) Cerebral atrophy in young cannabis smokers. Lancet 1: 143–147CrossRefGoogle Scholar
  134. Fischer C, Hatzidimitrion G, Wios J, Kath J, Recautre G (1995) Reorganization of Ascending 5-HT Axon Projections in Animal Previously Exposed to the Recreational Drug MDMA (’Ecstasy’). J of Neuroscience 8: 5476–5485Google Scholar
  135. Fischer J, Täschner K-L (1991) Flash back nach Cannabis-Konsum–eine Übersicht. Fortschr Neurol Psychiatr 59: 437–446CrossRefGoogle Scholar
  136. Fisher G, Steckler A (1974) Psychological effects, personality and behavioral changes attributed to marihuana use. Int J Addict 9: 101–126Google Scholar
  137. Fligiel SEG, Venkat H, Gong H, Tashkin DP (1988) Bronchial pathology in chronic marijuana smokers: a light and electron microscopic study. J Psychoactive Drugs 20: 33–42CrossRefGoogle Scholar
  138. Flom MC, Adams AJ, Jones RT (1975) Marijuana smoking and reduced pressure in human eyes: drug action or epiphenomenon ? Invest Ophthalm 14: 52–55Google Scholar
  139. Forstenhäusler D (1993) Synthetische Drogen. Kriminalistik 8–9: 533–558Google Scholar
  140. Frank M, Rosenthal E (1974) Marijuana Grower’s Guide. And/Or Press, San FranciscoGoogle Scholar
  141. Franks HM, Starmer GA, Chesher GB, Jackson DM, Hensley VR, Hensley WJ (1975) The interaction of alcohol and delta-9-tetrahydrocannabinol in man. Effects on psychomotor skills related to driving. Add Res Fond of Ontario, TorontoGoogle Scholar
  142. Frederick DL et al. (1985) Comparison of six cannabinoid metabolite assays. J Anal Tox 9: 116–120Google Scholar
  143. Frederking W (1955) LSD-25 and mescaline in psychotherapy. J Ment Dis 121: 70–77Google Scholar
  144. Freedman DX (1963) Psychotomimetic drugs and brain biogenic amines. Am J Psychiatry 119: 843–850Google Scholar
  145. Fried PA (1977) Behavioral and electroencephalographic correlates of the chronic use of marihuana–a review. Bull Narc 29 /2: 29–34Google Scholar
  146. Friedberg C (1965) Des Banisteriopsis utilisés comme drogue en Ameriqué du sud. J Agric Trop Bot Appl 12:403–437, 550–594, 729–780Google Scholar
  147. Furst PT (1971) Ariocarpus retusus, the “false peyote” of Huichol tradition. Econ Bot 25 /1: 182–187CrossRefGoogle Scholar
  148. Furst PT (ed) (1972) Flesh of the gods: The ritual use of hallucinogens. Prager, New YorkGoogle Scholar
  149. Furst PT (1976) Hallucinogens and culture. Chandler and Sharp, San FranciscoGoogle Scholar
  150. Galanter M, Wyatt R, Lemberger L et al. (1972) Marijuana intocication: Interaction between physiologic effects and subjektive experience. Sciene 176: 934–936Google Scholar
  151. Gale EN, Guenther G (1971) Motivational factors associated with the use of Cannabis. Br J Addict 13: 30–36Google Scholar
  152. Gaoni Y, Mechoulam R (1964) Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Sci 86: 136–147Google Scholar
  153. Garrett ER, Hunt CA (1977) Separation and analysis of A’-tetrahydrocannabinol in biologi- cal fluids by high-pressure liquid chromatopgraphy and GLC. J Pharm Sci 66: 20–26CrossRefGoogle Scholar
  154. Gautier T (1846) Le club des hachichins. Revue des Deux MondesGoogle Scholar
  155. Gerlach D, Schilling S (1984) Phencyclidin, Hinweise zur Erkennung und Behandlung von PCP-Intoxikationen. Suchtgefahren 30: 273–279Google Scholar
  156. Gielsdorf W, Klug E (1981) Neues Rauschmittel auf dem Drogenmarkt: 2,5-Dimethoxy-4bromamphetamin ( DOB ). Dtsch ApothZ 20: 1003–1005Google Scholar
  157. Gilmour DG, Bloom AD, Kusum PL, Robbins ES, Maximilian C (1971) Chromosomal aberrations in users of psychoactive drugs. Arch Gen Psychiatry 24: 268–272CrossRefGoogle Scholar
  158. Goenchea S, Dieckhöfer K (1972) Zur Toxizität von Cannabis. 2. Mitteilung. Med Welt 23: 1148–1151Google Scholar
  159. Goodall CR, Basteyns BJ (1995) A reliable method for the detection, confirmation, and quantitation of cannabinoids in blood. J Anal Toxicol 19: 419–426Google Scholar
  160. Goode E (1970) The marijuana smokers. Basic, New YorkGoogle Scholar
  161. Gorman M, Neuss N, Cone NJ (1965) Vinca alkaloids, XVII. Chemistry of catharanthine. J Am Chem Soc 87: 93–98Google Scholar
  162. Gostomzyk JG, Gewecke M, Eisele G (1971) Vergleichende Untersuchungen zur Verkehrs- tauglichkeit nach Haschischkonsum und nach einer Kurznarkose. Med Welt 22: 1785Google Scholar
  163. Gostomzyk JG, Parade P, Gewecke H (1973) Rauschmittelgenuss und Leistungsfähigkeit ( Untersuchungen zur Energiebildung unter Haschisch ). Z Rechtsmed 73: 131–136Google Scholar
  164. Granier M (1962) Native halluzinogene Arzneimittel aus Piptadenia. Bull an Narcotics 17: 29Google Scholar
  165. Green KS (1984) Discussion of the use of marihuana, ethanol, and other drugs among drivers killed in single vehicle crashes. J Forensic Sci 29: 16–21Google Scholar
  166. Green K (1975) Marihuana and the eye. Invest Ophthalm 14: 261–263Google Scholar
  167. Grenn K, Podos SM (1974) Antagonism of arachidonic acid induced ocular effects by delta-tetrahydrocannabinol. Invest Ophthalm 13: 422–429Google Scholar
  168. Green AR, Gross AJ, Goodwin GM (1995) Review of the pharmacology of MDMA. Psychopharmacol 119: 247–260CrossRefGoogle Scholar
  169. Green AR, Goodwin GM (1996) Ecstasy and neurodegeneration. Brain Med J 312: 1493CrossRefGoogle Scholar
  170. Green K, Kim K (1976) Interaction of adrenergic antagonists with prostaglandin E2 and tetrahydrocannabinol in the eye. Invest Ophthalm 15: 102–112Google Scholar
  171. Grinker RR (1964) Bootlegged ecstasy. Jama 187: 768CrossRefGoogle Scholar
  172. Grinspoon L. Bakalar JB (1981) Psychedelic drugs reconsidered. Basic, New York Grof S ( 1983 ) LSD-Psychotherapie. Klett-Cotta, StuttgartGoogle Scholar
  173. Gröger D (1966) Fortschritte der Chemie und Biochemie der Mutterkornalkaloide. Fortschr Chem Forsch 6: 159–164CrossRefGoogle Scholar
  174. Gross D (1971) Vorkommen, Struktur und Biosynthese natürlicher Piperidinverbindungen. Fortschr Chem Org Naturstoffe 29: 1–8Google Scholar
  175. Grotenhermen F, Huppertz R (1997) Hanf als Medizin. Hang/Hüthig, HeidelbergGoogle Scholar
  176. Gruenwaldt G (1971) Haschisch, Marihuana, LSD–Eigenschaften, Bedeutung, Gefahren. Saarl Ärztebl 24: 33–37Google Scholar
  177. Grupp SE (1972) Multiple drug use in a sample of experienced smokers. Int J Addict 7: 481–491Google Scholar
  178. Gudelsky GA, Yamamoto BK, Nash JF (1994) Potentiation of 3,4-methylendioxymethamphetamine-induced dopamine release and sorotonin neurotoxicity by 5-HT2 agonists. Eur J Pharmacol 264: 325–330CrossRefGoogle Scholar
  179. Haan J, Binder M (1980) Psychotrope Drogen: Halluzinogene und Psychostimulantien. Intern Welt 5: 153–160Google Scholar
  180. Haenel TA (1970) Kulturgeschichte und heutige Problematik des Haschischs. Pharmakopsychiat Neuropsychopharmakol 3:89- l 15Google Scholar
  181. Hansel W (1979) Struktur und Wirkung von Halluzinogenen. Chem in unserer Zeit 13:147 Hai H (1984) Das Hanfhandbuch. Piper, Löhrbach ( Der grüne Zweig, Bd. 73 )Google Scholar
  182. Halikas JA, Goodwin DW, Guze SB (1972) Marihuana use and psychiatric illness. Arch Gen Psychiatry 27: 162–165CrossRefGoogle Scholar
  183. Hallucinogenic and Psychedelic Drug Synthesis. Manual (1976) Salt and Pepper Syndicate. Lawrence/KSGoogle Scholar
  184. Hansjakob T (1999) Hanfshops–Gesundheitszentren oder Drogenumschlagplätze ? Kriminalistik 4: 273–277Google Scholar
  185. Heinemann C (1973) Nachlassende Wirkung initialer Rauscherlebnisse und Dosissteigerung beim Haschischkonsumenten. Med Klin 68: 826–830Google Scholar
  186. Harding R, Knight F (1973) Marihuana-modified mania. Arch Gen Psychiatry 29: 635–637CrossRefGoogle Scholar
  187. Harner MJ (ed) (1973) Hallucinogens and shamanism. Oxford Univ Press, LondonGoogle Scholar
  188. Harvey DJ (1985) Marihuana 1984. IRL Press, OxfordGoogle Scholar
  189. Harzer K (1982) Nachweis von LSD in Körperflüssigkeiten mit Hochdruckflüssigkeitschromatographie. J Chromatogr 249: 205–211CrossRefGoogle Scholar
  190. Hashimoto K et al. (1992) Effects of benzylpiperazine derivatives on the neurotoxicity of MDMA in rat brain. Brain Res 590/1–2: 341–344Google Scholar
  191. Hasse HE, Waldmann H (1971) “Flashback”: Spontane psychotische Episoden als Folgeerscheinung des Phantasticagebrauchs Jugendlicher. Arch Psychiatr Nervenkr 214: 399439Google Scholar
  192. Hawkes JG et al. (eds) (1979) The biology and taxonomy of the solanaceae. Academic Press, LondonGoogle Scholar
  193. Hawks RL (1982) The constituentes of cannabis and the disposition and metabolism of cannabinoids. Nat Int Drug Abuse Res Monogr Ser 42: 125–137Google Scholar
  194. Heath RG (1976) Marihuana and delta 9 tetrahydrocannabinol: Acute and chronic effects an brain function of monkeys. In: Braude MC, Szara S (eds) Pharmacology of marihuana. Raven, New York, pp 345–356Google Scholar
  195. Heath RG, Fitzjarrell AT, Garey RE, Myers WA (1979) Chronic marihuana smoking: Its effets on function and structure of the primate brain. In: Nahas GG, Paton WDM (eds) Marihuana: Biological effects. Pergamon, New York, pp 713–730Google Scholar
  196. Heim ME (1982) Cannabis und Cannabinoide. Fortschr Med 9: 343–346Google Scholar
  197. Heim R (1967) Nouvelles investigations sur les champignons hallucinogènes. Editions des Musées Nationaux Histoire, ParisGoogle Scholar
  198. Heim R, Wasson RG (1958) Les champignons hallucinogènes du Mexique. Editions des Musées Nationaux Histoire, ParisGoogle Scholar
  199. Heimann H (1961) Ausdrucksphänomenologie der Modellpsychosen (Psilocybin). Psychiat Neurol 141: 69–100CrossRefGoogle Scholar
  200. Heinemann C (1971) Klinisch beobachtete Folgeerscheinungen nach Haschischkonsum. Med Klin (Munich) 66: 1648–1653Google Scholar
  201. Helmer R, Wunder R, Zellmann K, Haesen D (1972) Experimentelle Untersuchungen zur Fahrtüchtigkeit nach Einnahme von Haschisch. Blutalkohol 4: 213–220Google Scholar
  202. Henderson GL (1988) Designer drugs, past history and future prospects. J Forensic Sci 33 /2: 569–575Google Scholar
  203. Henderson RL, Tennant FS, Guerry R (1972) Respiratory manifestations of hashish smoking. Arch Otolarnygol 95: 248–251CrossRefGoogle Scholar
  204. Henry JA (1999) Ecstasy and the dance of death. Brit Med J 305 /7: 5–6Google Scholar
  205. Hepler RS, Frank IM (1971) Marihuana smoking and intraocular Pressure. Jama 217: 1392Google Scholar
  206. Herer J (1993) Die Wiederentdeckung der Nutzpflanze Hanf-Cannabis-Marihuana. 2000, Frankfurt am MainGoogle Scholar
  207. Herha J (1974) Haschisch und Marihuana–eine Übersicht. Naturwissenschaften 61: 90–94CrossRefGoogle Scholar
  208. Herning RI, Jones RT, Peltzmann DJ (1979) Changes in human event relate potentials with prolonged delta-9-tetrahydrocannabinol ( THC) use. Electroencephalogr Clin Neurophysiol 47: 556–570Google Scholar
  209. Hesse M (1964/1968) Indolalkaloide in Tabellen. Springer, Berlin Heidelberg New YorkGoogle Scholar
  210. Hesse M (1974) Progress in mass spectrometry, vol 1: Indolalkaloide. Verlag Chemie, WeinheimGoogle Scholar
  211. Hingson R, Alpert JS, Day N et a. (1982) Effects of maternal drinking and marihuana use on fetal growth and development. Pediatrics 70: 539–546Google Scholar
  212. Hirschhorn K, Cohen MM (1968) Drug-induced chromosomal aberrations. Ann NY Acad Sci 151: 977–987Google Scholar
  213. Hochman JS, Brill NQ (1973) Chronic marijuana use and psychosocial adaption. Am J Psychiatr 130: 132–139Google Scholar
  214. Hoffer A, Osmond H (1967) The hallucinogens. Academic Press, New YorkGoogle Scholar
  215. Hoffmann D, Brunnemann KD, Gori GB, Wynder EL (1975) On the carcinogenicity of marijuana smoke. Res Adv Phytochem 9: 63–81CrossRefGoogle Scholar
  216. Hofmann A (1954) Die Isolierung weiterer Alkaloide aus Rauwolfia serpentina Benth. HeIv Chico Acta 37: 849–865Google Scholar
  217. Hofmann A et al. (1958) Psilocybin, ein psychotroper Wirkstoff aus dem mexikanischen Rauschpilz Psilocybe mexicana Heim. Experimentia XIV 3: 107–112Google Scholar
  218. Hofmann A (1960 a) Psychotomimetica, eine Übersicht. Svensk Kem Tidskr 72:79–88Google Scholar
  219. Hofmann A (1960 b) Die psychotropen Wirkstoffe der mexikanischen Zauberpilze. Chimia 14:309–318Google Scholar
  220. Hofmann A (1960 c) Isolierung von Lysergsäurealkaloiden aus der mexikanischen Zauberdroge Ololiuqui. Experimentia 16:414–420Google Scholar
  221. Hofmann A (1961) Die Wirkstoffe der mexikanischen Zauberdroge Ololiuqui. Planta Med 9: 354–367CrossRefGoogle Scholar
  222. Hofmann A (1964) Die Mutterkornalkaloide. Enke, StuttgartGoogle Scholar
  223. Hofmann A (1967) Psychoaktive Stoffe der Pflanzen. Therapiewoche 35: 40–47Google Scholar
  224. Hofmann A (1979) LSD - mein Sorgenkind. Klett-Cotta. Stuttgart.Google Scholar
  225. Hofmann A (1981) LSD ist eine sakrale Droge (Interview mit Dr. Hofmann). Psycho] Heute 4: 55–61Google Scholar
  226. Hofmannn A, Tscherter H (1960) Isolierung von Lysergsäurealkaloiden aus der mexikanischen Zauberdroge Ololiuqui. Experimantia XVI /9Google Scholar
  227. Hokkanen E, Waltimo O, Kallauranta J (1978) Toxic effects of ergotamine used for migraine. Headache 18: 95–98CrossRefGoogle Scholar
  228. Hole G (1967) LSD und verwandte Halluzinogene. Geschichte–Wirkung–Gebrauch und Gefahren. Mmw 109: 1389–1397Google Scholar
  229. Hollister LE (1968) Chemical psychoses. LSD and related drugs. Thomas, Springfield/ILGoogle Scholar
  230. Hollister LE (1986) Health Aspects of Cannabis. Pharmacol Rev 38: 1–20Google Scholar
  231. Hollister LE, Gillespie HK, Ohlsson A (1981) Do plasma concentrations of A9-tetrahydrocannabinol reflect the degree of intoxication ? J Clin Pharm 21: 171s - 177sGoogle Scholar
  232. Hollister LE, Richards RK, Gillspie HK (1986) Comparison of A9-tetrahydrocannabinol and synhexyl in man. Clin Pharmacol Ther 9: 783–791Google Scholar
  233. Honecker HC, Coper C (1970) Dünnschichtchromatographische Nachweismethode von Opium als Beimengung in Haschisch-Proben. Dtsch Med Wochenschr 42: 441–443Google Scholar
  234. Horowitz MJ (1969) Flashbacks: recurrent intrusive images after the use of LSD. Am J Psychiatry 126: 147–151Google Scholar
  235. Huestis MA, Henningfield JE, Lone EJ (1992) Blood Cannabinoids. I. Absorption of THC and formation of 11-OH-THC and THCCOOH during and after smoking Marihuana. J Anal Toxikol 16: 276–282Google Scholar
  236. Hunt CA, Jones RT (1980) Tolerance and disposition of tetrahydrocannabinbol in man. J Pharm Exp Ther 215: 35–44Google Scholar
  237. Huxley A (1972) The doors of perception (dtsch Übers: Die Pforten der Wahrnehmung. Piper, München )Google Scholar
  238. Isbell H, Gorodetzky CW, Jasinsky D, Claussen U. Spulak F, Korte F (1967) Effects of delta-9-transtetrahydrocannabinol in man. Psychopharmacologia (Berlin) 11: 184–188CrossRefGoogle Scholar
  239. Jacobson CB, Berlin CM (1972) Possible reproductive detriment in LSD users. Jama 222: 1367–1373CrossRefGoogle Scholar
  240. Jakubovic A, McGeer D (1972) Inhibition of rat brain protein by cannabinoids in vitro. Can J Biochem 50: 654–660CrossRefGoogle Scholar
  241. Janowsky DS, Meacham MP, Blaine JD, Schoor M, Bozetti LP (1976 a) Simulated flying performance after marihuana intoxication. Aviat Space Environ Med 47: 124–128Google Scholar
  242. Janowsky DS et al. (1976 b) Marijuana effects an simulated flying ability. Am J Psychiatry 133:384–388Google Scholar
  243. Johnson S, Domino EF (1971) Some cardiovascular effects of marihuana smoking in normal volunteers. Therapeutics 12: 762–768Google Scholar
  244. Johnstone RE (1973) A Ketamine trip. Anesthesiol 39: 460–461CrossRefGoogle Scholar
  245. Jones AB, ElSohly HN et al. (1984) Analysis of the Major Metabolite of Delta-9-tetrahy- drocannabinol in Urine. An Comparison of Five Methods. J Anal Toxikol 8: 249–251Google Scholar
  246. Jones H, Jones HC (1977) Sensual drugs. Cambrigde Univ Press, CambridgeGoogle Scholar
  247. Jones HC, Lovinger PW (1985) The marihuana question. Mead, New YorkGoogle Scholar
  248. Jones R (1977) Human effects. NIDA Res Monogr 14: 128–178Google Scholar
  249. Joyce CRB, Curry SH (1970) The botany and chemistry of cannabis. Churchill, LondonGoogle Scholar
  250. Karler R (1977) Toxicological and pharmacological effects. NIDA Res Monogr 14: 55–66Google Scholar
  251. Kang S et al. (1970) Correlation between activity and electronic state of hallucinogenic amphetamines. Nature 226: 645–647CrossRefGoogle Scholar
  252. Kanter SL, Hollister LE (1977) Marihuana metabolites in urine of man. Res Commun Chem Pathol Pharmacol 17: 421–431Google Scholar
  253. Kaiser C, Gold R (1974) Perception, psychedelics and social change. J Psychedelic Drugs 6: 30–35CrossRefGoogle Scholar
  254. Kaplan HS (1971) Psychosis associated with marijuana. NY State J Med 71: 433–435Google Scholar
  255. Karler R, Cely W, Turkanis SA (1974 a) Anticonvulsant properties of A9-tetrahydrocannabinol and other cannabinoids. Life Sci 15: 931–947Google Scholar
  256. Karler R, Cely W, Turkanis SA (1974 b) A study of the development of tolerance to an anticonvulsant effect of delta-9-THC and cannabidiol. Res Commun Chem Pathol Pharmacol 9: 23–29Google Scholar
  257. Kintz P, Cirimele V, Ludes B (2000) Testing for cannabis in saliva of impaired drivers. Blutalkohol 37: 89–92Google Scholar
  258. Katzung W (1990) Drogen: Informationen in Übersichten IV. Abhängigkeit vom Cannabis-Typ. Leitdroge THC. Medizin aktuell 16: 568–570Google Scholar
  259. Katzung W et al. (1991) Psilocybe-Pilze-Drogen vor der Haustür ? Medizin aktuell 17: 654655Google Scholar
  260. Katzung W, Harfst G (2001) Synthetische Amphetamin-Drogen. Holger Harfst Verlag, WürzburgGoogle Scholar
  261. Kaymakcalan S (1975) Potential dangers of cannabis. Int J Addict 10: 721–735Google Scholar
  262. Keller K, Stahl E (1982) Kalmus: Inhaltsstoffe und Asarongehalt bei verschiedenen Herkünften. Dtsch Apoth Z 122 /48: 2463–2466Google Scholar
  263. Kelly P, Jones RT (1992) Metabolism of tetrahydrocannabinol in frequent and infrequent marijuana users. J Anal Toxicol 16: 228–235Google Scholar
  264. Kemali M, Kemali D (1980) Lysergic acid diethylamide: Morphological study of its effects on synapsis. Psychopharmacol 69: 315–317Google Scholar
  265. Kemp PM, Abukhalaf JE, Manno BR et al. (1995) Cannabinoids in humans. I. Analysis of delta-9-tetrahydrocannabinol and six metabolits in urine using GC-MS. J Anal Toxicol 19: 285–291Google Scholar
  266. Kennedy AB, Rätsch C (1985) Datura: Aphrodisiac ? High Frontiers, BerkeleyGoogle Scholar
  267. Keup W (1967) Psychotic symptoms due the cannabis abuse (a survey of newly admitted mental patients). Dis Nery Syst 31: 119–126Google Scholar
  268. Keup W (1990) Analoga kontrollierter Substanzen–Entwicklung des Missbrauchs in der BRD. Suchtgefahren 36: 251–259Google Scholar
  269. Kielholz P, Hobi V, Ladewig D, Miest P, Richter R (1973) An experimental investigation about the effect of cannabis on car absorption. Pharmakopsychiatry 6: 91–103CrossRefGoogle Scholar
  270. Kintz P, Cirimele V (1997) Testing human blood for cannabis by GC/MS. Biomed Chromatogr 11: 371–373CrossRefGoogle Scholar
  271. Kintz P, Girond C (1997) Immunoassay responses of MBDB. J Anal Toxicol 21: 589–590Google Scholar
  272. Kleiner D (1992) Eine psychotische Episode mit Verkehrsunfall nach Cannabis-Konsum. Sucht 5: 345–346Google Scholar
  273. Kleiner D, Stosberg K, Täschner K-L (1993) Erfahrungen mit Cannabiskonsumenten — Er- gebnisse einer Umfrage bei Kliniken und Drogenberatungsstellen. Sucht 1: 33–45Google Scholar
  274. Klonoff H (1974) Marihuana and driving in real-life situations. Science 32: 317–323CrossRefGoogle Scholar
  275. Klonoff H (1983) Acute psychological effects of marihuana in man, including acute cognitive psychomotor and perceptual effects in driving. In: Fehr O’Brien K, Kalant H (eds) Cannabis and health hazards. Addiction Research Foundation, Toronto, pp 88–96Google Scholar
  276. Knapp H (1991) GABA ist an allem schuld. Suchtreport 5 /2: 28Google Scholar
  277. Knecht S (1962) Magische Pilze. Über die mexikanische Pilzzeremonie. Med Welt 35: 1853–1859Google Scholar
  278. Kniesel M (1994) Nach der Entscheidung des BVerfG zur Strafbarkeit weicher Drogen. Anfang vom Ende der Drogenpolitik durch Strafrecht. Zrp 9: 352–358Google Scholar
  279. Koch CAL (1864) Der Hanf. Allg Z Psychiatr 21: 13–19Google Scholar
  280. Kolansky H, Moore WT (1971) Effects of marihuana on adolescents and young addults. Jama 216: 486–492CrossRefGoogle Scholar
  281. Konzett H (1981) Halluzinogene: LSD, Psilocybin und Mescalin. Dtsch Ärztebl 78: 283288Google Scholar
  282. Korte F et al. (1965) THC-Carbonsäure, ein neuer Haschisch-Inhaltsstoff. Angew Chem 77: 33–35Google Scholar
  283. Kovar K-A (1989) Designer-Drugs - Synthetische Suchtstoffe der 2. Generation. In: Kath. Sozialethische Arbeitsstelle (Hrsg) Designer Drogen. Zum Gefährdungs-und Suchtpotential synthetischer Drogen. Hoheneck, HammGoogle Scholar
  284. Kovar K-A, Rösch C, Rupp A (1990) Synthetische Suchtstoffe der 2. Generation. 1. Mitt.: Amphetamine und andere Arylalkylamine. Pharm in unserer Zeit 19 /3: 99–107CrossRefGoogle Scholar
  285. Krumsiek L (1975) Haschischöl. Kriminalistik 3: 124–128Google Scholar
  286. Kuehne ME (1964) The total synthesis of vincamine. J Am Chem Soc 86: 2946–2973CrossRefGoogle Scholar
  287. Kuehnle J, Mendelson JH, Davis DR, New PFJ (1977) Computer tomographic examination of heavy marihuana smokers. Jama 237 /12: 1231–1232CrossRefGoogle Scholar
  288. Kumar S, Kunwar KB (1972) Chromosome abnormalities in cannabis addicts. J Assoc Phys India 19: 193–195Google Scholar
  289. Kuntz M (1997) Du liebst alle und alle lieben Dich. Die Suchtarbeit mit Ecstasykonsumenten. Suchtreport 1: 47–51Google Scholar
  290. Kutney JP, Brown RT, Piers E (1966) The absolute configuration of the Iboga alkaloids. Can J Chem 44: 637–645CrossRefGoogle Scholar
  291. Kvalseth TO (1977) Effects of marihuana on human reaction time and motor control. Percept Mot Skills 45: 935–939CrossRefGoogle Scholar
  292. LaBarre W (1960) Twenty years of peyote studies. Curr Anthropol 1: 45–60CrossRefGoogle Scholar
  293. LaBarre W (1972) Hallucinogens and the shamanic origin of religion. In: Furst P T (ed) Flesh of the Gods: The ritual use of hallucinogens. Praeger, New York, pp 36–49Google Scholar
  294. La Valle S (1984) Hashish. Quarter Books, London New York MelbourneGoogle Scholar
  295. Law B (1984) Confirmation of cannabis use by the analysis of A9-THC metabolits in blood and urine by combined HPLC and RIA. J Anal Toxicol 8: 19–22Google Scholar
  296. Law B, Mason PA, Moffat AC et a1. (1984) Forensic Aspects of the Metabolism and Excretion of Cannabinoids Following Oral Ingestion of Cannabis Resin. J Pharm Pharmacol 36: 289–294CrossRefGoogle Scholar
  297. Law FCP (1980) Metabolic disposition and potential toxicity of PCC in rats. Res Comm in Subst of Abuse 1 /3: 273Google Scholar
  298. Leaf RC, De Bold RC (1967) LSD, man and society. Wesleyan Univ Press, ConnecticutGoogle Scholar
  299. Leary T (1962) How to change behaviour. (Proceedings of X IV. International Congress on Applied Psychology, Copenhagen )Google Scholar
  300. Leary T (1964) The religious experience. Psychedelic Rev 3:30–42 Leary T ( 1970 ) Politik der Ekstase. Wegner, HamburgGoogle Scholar
  301. Leistenfels H von (oJ) Pilze: Speisepilz-Zucht Rauschpilz-Erkennung. Pieper and Die Grüne Kraft, Löhrbach (Grüner Zweig, Bd 65)Google Scholar
  302. Lemberger L, Rubin A (1975) The physiologic disposition of marihuana in man. Life Sci 17: 1637–1642CrossRefGoogle Scholar
  303. Leonhardt RW (1970) Haschischreport. Piper, München Leuenburger H ( 1969 ) Zauberdrogen. Goverts, StuttgartGoogle Scholar
  304. Leuner H (1971) Halluzinogene in der Psychotherapie. Pharmakopsychiatry 4: 333–351CrossRefGoogle Scholar
  305. Leuner H (1981) Halluzinogene. Huber, BernGoogle Scholar
  306. Levy JA, Munson AE, Harris LS, Dwewey WL (1975) Effects of delta-9-THC on the immune response of mice. Fed Proc 34: 782–789Google Scholar
  307. Lewin L (1927) Phantastica - Die betäubenden und erregenden Genußmittel (Nachdruck 1981 ). Volksverlag, LindenGoogle Scholar
  308. Lewin L (1929) Banisteria Caapi. Stilke, BerlinGoogle Scholar
  309. Lewis EG, Peters BA, Dustman RE, Straight RC, Beck EC (1976) Sensory, perceptual, motor and cognitive functioning and subjective reports following oral admimistration of delta-9-THC. Psychopharmacologia (Berlin) 47: 141–148CrossRefGoogle Scholar
  310. Liden CB, Lovejoy FH, Castello CE (1975) Phencyclidine–9 Cases of Poisoning. Jama 234 /5: 513–516CrossRefGoogle Scholar
  311. Lidz T, Rothenberg A (1970) Psychedelismus: Die Wiedergeburt des Dionysos. Psyche 24: 359–374Google Scholar
  312. Linszen H et al. (1994) Cannabis Abuse and the Course of Recent-Onset Schizophrenic Disorders. Arch Gen Psychiatry 51: 273–279CrossRefGoogle Scholar
  313. Lockwood TE (1979) The ethnobotany of brugmansia. J Ethnopharmacol 1: 147–164CrossRefGoogle Scholar
  314. Löhrer F (1997) Biogene Suchtmittel. Ariadne, Aachen Ludlow FH ( 1981 ) Der Haschisch-Esser. Sphinx, BaselGoogle Scholar
  315. Luisada PV, Brown BJ (1976) Clinical Management of Phencyclidine Psychosis. Clin Toxicol 9 /4: 539–545CrossRefGoogle Scholar
  316. Lundberg GD, Gupta RC, Montgomery SH (1976) Phencyclidine: Patterns Seen in “Street Drug” Analysis. Clin Toxicol 9 /4: 503–511CrossRefGoogle Scholar
  317. Lyon RA et al. (1986) MDMA Stereoselective interactions at brain 5-HT1 and 5-HT2 receptors. Psychopharmacol 88: 525–526Google Scholar
  318. Madsen W (1955) Shamanism in Mexico. Southwest J Anthropol 2 /1: 48–57Google Scholar
  319. Manden M, Skopp G, Mattern R, Aderjan R (2000) GC/MS-Bestimmung von THCCOOH im Serum: Vergleich verschiedener Aufarbeitungsmethoden und Einfluß von THCCOOH-Glucuronid. Blutalkohol 37: 48–56Google Scholar
  320. Meatherall RC, Warren RJ (1993) High urinary cannabinoids from a hashish body packer. J Anal Toxicol 17: 439–440Google Scholar
  321. Manno JE, Kiplinger GF, Haine SE, Bennett IF, Forney RB (1970) Comparative effects of smoking marihuana or placebo on human motor and mental performance. Clin Pharmacol Ther 11: 808–815Google Scholar
  322. Margolis JS, Clorfene R (1979) Der Grassgarten. Volksverlag, LindenGoogle Scholar
  323. Marijuana and Health (1980) 8th Annual Report to the US Congress from the Secretary of Health, Education and Welfare, Washington/DCGoogle Scholar
  324. Marzell H (1964) Zauberpflanzen–Hexengetränke. Kosmos 241: 47–55Google Scholar
  325. Mason AP, McBay AJ (1984) Ethanol, marijuana and other drugs in 600 drivers killed in single-vehicle crashes in North-Carolina 1978–1981. J Fornsic Sci 29: 987–1026Google Scholar
  326. Mason AP, McBay AJ (1985) Cannabis. Pharmacology and Interpretation of effects. J Forensic Sci 30: 615–631Google Scholar
  327. McBay AJ (1985) Marijuana testing and litigation. J Forensic Sci 30: 987–994Google Scholar
  328. McBay AJ (1988) Interpretation of Blood and Urine Cannabinoid Concentrations. J Forensic Sci 33: 875–883Google Scholar
  329. McBurney LJ, Bobbie BA, Sepp LA (1986) GC/MS and EMIT Analyses for Delta-9-Tetrahydrocannabinol Metabolites in Plasma and Urine of Human Subjects. J Anal Toxicol 10: 55–64Google Scholar
  330. McCann UB, Ridenour A, Graham Y, Ricaurte G (1994) Serotonin Neurotoxicity after MDMA (’Ecstasy’): A controlled Study in Humans. Am Coll of Neuropsychopharmacol 2: 129–138 9Google Scholar
  331. McCullum NK, Shaw SM (1981) Chromatographic analysis for A9-tetrahydrocannabinol in blood and brain. J Anal Toxicol 5: 148–149Google Scholar
  332. McDonald PA, Martin CF, Woods DJ, Baker PB, Gough TA (1984) An analytical study of illicit lysergide. J Forensic Sci 29: 120–130Google Scholar
  333. McGlothlin WS, Cohen S, McGlothlin M (1964) Short-term effects of LSD on anxiety, attitudes and performance. J Nery Ment Dis 139: 266–273CrossRefGoogle Scholar
  334. McGlothlin WS, Cohen S, McGlothlin M (1970) Long lasting effects of LSD on normals. J Psychedelic Drugs 3: 20–31CrossRefGoogle Scholar
  335. McLeary JA, Sypherd PS, Walkington DJ (1960) Antibiotic activity of an extract of peyote Lophophora williamsii ( Lemaire) Coulter. Econ Bot 14: 247–249Google Scholar
  336. Mechoulam R (1970) Marihuana chemistry. Science 168: 1159–1166CrossRefGoogle Scholar
  337. Mechoulam R (1973) Marihuana-Chemistry, pharmacology, metabolism and clinical effects. Academic Press, LondonGoogle Scholar
  338. Mechoulam R, Gaoni Y (1965) A total synthesis of d,1-delta-tetrahydrocannabinol, the active constituent of hashish. J Am Chem Soc 87: 3273–3275CrossRefGoogle Scholar
  339. Mechoulam R et al. (1994) Search for endogenous ligands of the cannabinol receptor. Biochem Pharmacol 48: 1537–1540CrossRefGoogle Scholar
  340. Meck B (1981) Die Assassinen. Econ, Düsseldorf WienGoogle Scholar
  341. Melges FT, Tinklenberg JR, Hollister LE, Gillespie HK (1970) Marihuana and temporal disintegration. Science 6: 1118–1120CrossRefGoogle Scholar
  342. Mendelsohn JH (ed) (1974) The use of marihuana. Plenum, New YorkGoogle Scholar
  343. Mendelsohn JH (1987) Marijuana. In: Meltzer HY (ed) Psychopharmakology, Raven, New York, pp 60–67Google Scholar
  344. Merkus F et al. (1971) TLC, GLC, MS of cannabidivarin, tetrahydrocannabivarin and cannabivarin. Acta Pharm Suec 8Google Scholar
  345. Miller LL (ed) (1974) Marijuana - effects on human behavior. Academic Press, New York San Francisco LondonGoogle Scholar
  346. Miller LT, Cornett T, McFarland D (1978) Marijuana: an analysis of storage and retrieval deficits in memory with the technique of restricted reminding. Pharmacol Biochem Behav 8: 327–332CrossRefGoogle Scholar
  347. Miller RA (1983) The magical and ritual use of herbs. Destiny, New YorkGoogle Scholar
  348. Moeller MR, Doerr G, Watts S (1992) Simultaneous quantitation of delta-9-tetrahydrocannabinol (THC) and 11-nor-9-carboxy-delta-9-tetrahydrocannabinol ( THC-COOH) in serum by GC/MS using deuterated internal standards and its application to a smoking stydy and forensic cases. J Forensic Sci 37: 969–983Google Scholar
  349. Möller-Nehring E, Luderer H-J (1997) Ist die Angst vor Ecstasy berechtigt ? Fortschr Med 7: 28–34Google Scholar
  350. Morton JF (1981) Atlas of medical plants of middel america. Thomas, Springfield/ILGoogle Scholar
  351. Moskowitz H, Sharma S, McGlothlin WS (1972) Effetcs of marihuana upon peripheral vision as a function of the information processing demand in central vision. Percept Mot Skills 35: 876–882CrossRefGoogle Scholar
  352. Moskowitz H, McGlothlin WS (1974) Effects of marihuana on auditory signal detection. Psychopharmacologia (Berlin) 48: 137–145Google Scholar
  353. Munch JC (1974) Phencyclidine: Pharmakology and Toxicology. Bull Narc 26 /4: 9–17Google Scholar
  354. Murray JB (1985) Marihuana’s Effects on Human Cognitive Functions, Psychomotor Functions, and Personality. J Gen Psychol 113: 23–55CrossRefGoogle Scholar
  355. Myerhoff BG (1980) Der Peyote Kult. Trikont, MünchenGoogle Scholar
  356. Nahas GG (1972) Toxicology and pharmacology of cannabis sativa with special reference to delta-9-THC. Bull Narc 24: 11–27Google Scholar
  357. Nahas GG (1974) Effects of cannabis and cannabinoids on cell replication and replication and DNA synthesis in man. J Pharmacol 5: 71–78Google Scholar
  358. Nahas GG (1975) Marihuana - Deceptive Weed. Raven Press, New YorkGoogle Scholar
  359. Nahas GG (1979) Keep off the grass. Pergamon, Oxford New YorkGoogle Scholar
  360. Nahas GG (1982) Hashish in Islam, 9th to 18th century. Bull NY Acad Med 58 /9: 814–831Google Scholar
  361. Nahas GG (ed)(1984) Marihuana in science and medicine. Raven, New YorkGoogle Scholar
  362. Nahas GG (1986) Cannabis: toxicological properties and epidemiological aspects. Med J Anst 145: 82–87Google Scholar
  363. Nahas GG (1991) Es ist doch nur Marihuana. Suchtreport 5 /2: 18–27Google Scholar
  364. Nahas GG, Patton WDM (eds) (1979) Marihuana. Biological effects analysis, metabolism, cellular responses, reproduction and brain. Pergamon, OxfordGoogle Scholar
  365. Nahas GG, Sucia-Foca N, Armand J-P, Morishima A (1974) Inhibition of cellular mediated immunity in marihuana smokers. Science 183: 419–420CrossRefGoogle Scholar
  366. Nahas GG, Desoize B, Hsu J, Morishima A, Srinvasan PR (1975) Inhibition of nucleic acid and poteins synthesis by natural cannabinoids and olivetol. (Abstract, IV. Int. Congress of Pharmacology, Helsinki, p 495 )Google Scholar
  367. Nahas GG, Patton WDM, Idänpään Heikkilä JE (eds)(1976) Marihuana: chemistry, biochemistry and cellular effects. Springer, New YorkGoogle Scholar
  368. Nahas GG, Latour Z (1992) The human toxicity of marihuana. Med J Anst 156 /7: 495–497Google Scholar
  369. Nakamura GR, Meeks RD, Stall WJ (1990) Solid-Phase Extraction, Identification and Quantitation of 11-nor-Delta-9-Tetrahydrocannabinol-9-carboxylic Acid. J Forensic Sci 35: 792–796Google Scholar
  370. Negrete JC (1973) Psychological adverse effects of cannabis smoking. A tentative classification. Can Med Assoc J 108: 195–196Google Scholar
  371. Neu RL, Powes HO, King S, Gardner LI (1969) Cannabis and chromosomes. Lancet I: 675Google Scholar
  372. Neumeyer JL, Shagoury L (1971) Chemistry and pharmacology of marijuana. J Pharm Sci 60: 1433–1451CrossRefGoogle Scholar
  373. Neuninger H (1988) Zur Bewertung von inländischen Cannabis-Produkten. Österr RichterZ 66: 127–130Google Scholar
  374. Nichols DE et al. (1986) Derivats of 1-(1,3-Benzodioxol-5-yl-butanamine): Representatives of a Novel Therapeutic Class. J Med Chem 29: 2009–2015CrossRefGoogle Scholar
  375. Nichols WW, Miller RC, Heneen W, Bradt C, Hollister L, Kanter S (1974) Cytogenetic studies on human subjects receiving marihuana and delta-9-tetrahydrocannabinol. Mutat Res 26: 413–417CrossRefGoogle Scholar
  376. Nolte F (2002) Cannabis im Straßenverkehr–Zur Inszenierung und Dramaturgie eines gesellschaftlichen “Problems”. Blutalkohol 39 (Suppl. 1): 17–20Google Scholar
  377. Novotny M, Lee MC, Keast D (1976) A possible chemical basis for the higher mutageni- city of marihuana smoke as compared to tobacco smoke. Experientia 32: 280–282CrossRefGoogle Scholar
  378. Nowlan R, Cohen S (1977) Tolerance to marihuana: heart rate and subjective “high”. Clin Pharmacol Ther 22: 550–555Google Scholar
  379. Ott J, Bigwood J (eds)(1978) Teonanacatl: Hallucinogenic mushroom of North America. Madrona, Seattle/WAGoogle Scholar
  380. O’Hearn E, Battaglia G, De Souza EB, Kuhar MJ, Molliver ME (1988) Methylendioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA) cause selective ablation of serotonergic axon terminals in forebrain: immunocytochemical evidence for neurotoxicity. J Neurosci 8: 2788–2803Google Scholar
  381. Ohlsson A, Lindgren JE, Wahlen A et al. (1980) Plasma delta-9-tetrahydrocannabinol concentrations and clinic effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 28: 409–416CrossRefGoogle Scholar
  382. Olvedi U (1972) LSD-Report. Suhrkamp, Frankfurt am Main Orzechowski G (1969) Halluzinogene Drogen, Med Welt 16: 955–963Google Scholar
  383. Oss OT, Oeric ON (1976) Psilocybin, magic mushrooms grower’s guide. And/Or Press, BerkeleyGoogle Scholar
  384. Ott J (1976) Hallucinogenic plants of North America. Wingbow, Berkeley/CAGoogle Scholar
  385. Pace HD, Davis A, Borgen LA (1971) Teratogenesia and marihuana. Ann NY Acad Sci 191: 123–128CrossRefGoogle Scholar
  386. Pahnke W (1963) Drugs and mysticism: An analysis of the relationship between psychedelic drugs and the mystical consciousness. Master’s thesis Univ of HarvardGoogle Scholar
  387. Payne RJ, Brand SN (1975) The toxicity of intravenously used marihuana. Jama 233: 351–354CrossRefGoogle Scholar
  388. Peeke SC, Jones RT, Stone GC (1976) Effects of practice an marihuana–induced changes in reaction time. Psychopharmacol 48: 159–163CrossRefGoogle Scholar
  389. Peel HW, Perrigo BJ (1981) Detection of cannabinoids in blood using EMIT. J Anal Toxicol 5: 165–167Google Scholar
  390. Perez-Reyes M, Owens SM, DiGuiseppe S (1981) The clinical pharmacology and dynamics of marihuana cigarette smoking. J Clin Pharmacol 21: 201s - 207sCrossRefGoogle Scholar
  391. Perez-Reyes M, DiGuiseppe S, Davis KH et al. (1982) Comparisation of effects of marihuana cigarettes of three different potencies. Clin Pharmacol Ther 31: 617–624CrossRefGoogle Scholar
  392. Peronka S, Newman M, Harris H (1988) Subjective Effects of DOM in Recreational Users. Neuropsychopharmacol 1: 273–277Google Scholar
  393. Perontka SJ (ed)(1990) Ecstasy, the clinical, pharmacological and neurotoxicological effects of the drug MDMA. Khiver Academic Publishers, BostonGoogle Scholar
  394. Petersen BH, Graham J, Lembeger L (1976) Marihuana, tetrahydrocannabinol and T-cell function. Life Sci 19: 395–400CrossRefGoogle Scholar
  395. Petersen RC (ed)(1977) Marihuana research findings. NIDA Res Monogr 14:205–218Google Scholar
  396. Petersen RC (ed) (1980) Marijuana research findings. NIDA Res Monogr 31: 69–85Google Scholar
  397. Petersen RC, Stillman RC (1978) Phencyclidine ( PCP) abuse: An appraisal. NIDA Res Monogr 21: 168–175Google Scholar
  398. Petrzilka T (1971) Chemie synthetischer Hanf-Derivate. Bull Schweiz Akad Med Wiss 27: 22–27Google Scholar
  399. Petrzilka T, Haefliger W, Sikemeier G, Ohloff G, Eschenmoser A (1967) Synthese und Chiralität des (-)-Cannabidiols. Heiv Chim Acta 50: 719–723CrossRefGoogle Scholar
  400. Peuckert W-E (1960) Hexensalben. Med Monatsspiegel 9: 169–174Google Scholar
  401. Poehlke T (1995) MDMA–Droge oder Medikament ? Westfäl Ärztebl 8: 16–19Google Scholar
  402. Pope HH Jr (1969) Tabernanthe iboga–an African narcotic plant of social importance. Econ Bot 23: 174–184CrossRefGoogle Scholar
  403. Priemer F, Grappmaier A, Ruby M et al. (1999) Pupillenverhalten unter akutem THC-Einfluß. Blutalkohol 32: 84–98Google Scholar
  404. Rivier L, Lindgren J-E (1972) Ayahuasca–South American hallucinogenic drink: ethnobotanical and chemical investigations. Econ Bot 24: 100–129Google Scholar
  405. Rabes M, Harm W (Hrsg)(1997) XTC und XXL: Ecstasy-Wirkungen, Risiken, Vorbeugungsmöglichkeiten und Jugendkultur. Rowohlt, ReinbekGoogle Scholar
  406. Raffauf RF, Flagler MB (1960) Alkaloids of the apocynaceae. Econ Bot 14: 37–46CrossRefGoogle Scholar
  407. Rakete G, Flüsmeier U (1997) Der Konsum von Ecstasy. Eine empirische Studie zu Mustern und psychosozialen Effekten des Ecstasykonsums. Bundeszentrale für gesundheitliche Aufklärung, Köln.Google Scholar
  408. Randall T (1992) “Rave” Scene, Ecstasy Use, Leap Atlantic. Jama 268: 1506–1509CrossRefGoogle Scholar
  409. Ranke-Graves R von (1985) Griechische Mythologie. Rowohlt, ReinbekGoogle Scholar
  410. Ray R, Prabhu GG, Mohan D, Nath LM, Neki JS (1978) Cannabis use. The association between chronic abuse and cognitive functions. Drug Alcohol Depend 3: 365–368Google Scholar
  411. Rayner R (1979) Pilze erkennen - leicht gemacht. Franck’sche Verlagsbuchhandlung, StuttgartGoogle Scholar
  412. Reed A, Kane W (1972) Phencyclidine (PCP). J Psychedelic Drugs 5 /1: 8–12CrossRefGoogle Scholar
  413. Reeve VC, Grant JD, Robertson W et al. (1983 a) Plasma concentration of delta-9-tetrahydrocannabinol and impaired motor function. Drug Alcohol Depend 11: 176–175Google Scholar
  414. Reeve VC, Robertson WB, Grant J ( 1983 b) Hemolyzed blood and serum levels of 49THC: Effects on the performance of roadside sobriety tests. J Fornesic Sci 28: 963–971Google Scholar
  415. Remschmidt H (1972) Haschisch und LSD. Physische und psychische Wirkungen. Med Klin 67:706–716, 781–786Google Scholar
  416. Renault PF, Schuster CR, Heinrich R, Freeman DX (1971) Marihuana: Standartized smo- king administration and dose effects on heart rate in humans. Science 174: 589–591Google Scholar
  417. Reynolds PC (1976) Clinical and Forensic Experiences with Phencyclidine. Clin Toxicol 9 /4: 547–552CrossRefGoogle Scholar
  418. Ricklin F (1989) Cannabis: harmloses Rauschgift ? Schweiz Med Wochenschr 119: 11731176Google Scholar
  419. Rösch C et al (1990) Synthetische Suchtstoffe der 2. Generation. 2. Mitt.: Analytik der Arylalkylamine. Pharm in unserer Zeit 19 /5: 211–221CrossRefGoogle Scholar
  420. Rodin E, Domino E, Porzak J (1970) The marijuana induced social high–Neurological and electroencephalographic concomitants. Jama 213: 1300–1202CrossRefGoogle Scholar
  421. Rosenthal E (1984) Marijuana beer. And/Or Press, BerkeleyGoogle Scholar
  422. Schönhofer PS (1973) Die Pharmakologie der Cannabis-Wirkstoffe. Arzneimittelforsch 23: 50–55Google Scholar
  423. Safford WE (1916) Identity of cohoba, the narcotic snuff of ancient Haiti. J Wash Acad Sci 6: 548–562Google Scholar
  424. Sahihi A (1989) Designer-Drogen: die neue Gefahr. Beltz, Weinheim BaselGoogle Scholar
  425. Sahihi A (1991) Designer-Drogen: Zwischen Hölle und Paradies. Suchtreport 5 /1: 42–47Google Scholar
  426. Sallan SE, Zinberg NE, Frei E (1975) Antiemetic effect of delta-9-THC in patients receiving cancer chemotherapy. N Eng J Med 293: 795–797CrossRefGoogle Scholar
  427. Sankar DVS (1975) LSD - A total study. PJD Publications, Westbury/NYGoogle Scholar
  428. Sankar DVS, Roszy PW, Geisler A (1969) Chromosome breakage in children treated with LSD-25 und UML-491. Compr Psychiatry 10: 406–410CrossRefGoogle Scholar
  429. Saunders N (1994) “Ecstasy”. Bilger, ZürichGoogle Scholar
  430. Saxton JE (1956) The indole alkaloids excluding harmine and strychnine. Q Rev 10: 108–112CrossRefGoogle Scholar
  431. Scherer S (1996) Cannabis als Genußmittel ? Zrp 5: 187–191Google Scholar
  432. Schleifer H (1973) Sacred narcotic plants of the New World Indians. Hafner,New York Schmidt D (1970) Halluzinogene aus Pflanzen. Naturwiss Rundschau 23: 5Google Scholar
  433. Schmidt P, Scheer N, Berghaus G (1995) Cannabiskonsum und Fahrtüchtigkeit. Kriminalistik 4: 241–246Google Scholar
  434. Schmiechen R et al. (1986) Carbolines - A new class of compounds with high affinity for benzodiazepine receptors. Sonderdruck: IXth Int. Symposium on Medicinal Chemistry, BerlinGoogle Scholar
  435. Schmitt G, Herbold M, Aderjan R (1999) Berechung der Nachweis-, der Erfassungs-und der Bestimmungsgrenze von Tetrahydrocannabinol ( THC) im Serum. Blutalkohol 36: 362–370Google Scholar
  436. Schreiber LH (1997) Das Urteil des BGH zu Ecstasy. Njw 12: 777–779Google Scholar
  437. Schrenk T von (1999) Internistische Komplikationen nach Ecstasy. Dtsch Ärztebl 96: A347–352Google Scholar
  438. Schultes RE (1941) A contribution to our knowledge of rivea corymbosa, the narcotic ololiuqui of the Aztecs. Harvard Botanical Museum, Cambrigde/MAGoogle Scholar
  439. Schultes RE (1965) Ein halbes Jahrhundert amerikanischer Ethnobotanik der Halluzinogene. Planta med 13: 125–129CrossRefGoogle Scholar
  440. Schultes RE (1969) Hallucinogens of plant origin. Science 163: 245–254CrossRefGoogle Scholar
  441. Schultes RE (1969/70) The plant kingdom and hallucinogens. Bull Narc 21:3–16, 22:25–53Google Scholar
  442. Schultes RE (1970 a) The botanical and chemical distribution of hallucinogens. Ann Rec Plant Physiol 21:571–590Google Scholar
  443. Schultes RE ( 1970 b) Botany and chemistry of cannabis. Churchill, LondonGoogle Scholar
  444. Schultes RE (1972) An overview of hallucinogens in the western hemisphere. In: Furst P T (ed) Flesh of the Gods: The ritual uses of hallucinogens. Praeger, New York, pp 3–54Google Scholar
  445. Schultes RE (1976) Hallucinogenic plants. Golden Press, New YorkGoogle Scholar
  446. Schultes RE, Hofmann A (1980) The botany and chemistry of hallucinogens. Thomas, Springfield/ILGoogle Scholar
  447. Schultes RE, Hofmann A (1995) Pflanzen der Götter. Die magischen Kräfte der Rauschund Giftgewächse. AT, AarauGoogle Scholar
  448. Schultz 0E, Haffner C (1958) Zur Kenntnis eines sedativen Wirkstoffes aus dem deutschen Faserhanf. Arch Pharm (Berlin) 291: 20–24CrossRefGoogle Scholar
  449. Schulz V (1984) Behandlung des Ergotismus. Fortschr Med 8: 189–190Google Scholar
  450. Schurz J (1970) Vom Bilsenkraut zum LSD. Frank’sche Verlagsbuchhandlung, StuttgartGoogle Scholar
  451. Schuster P, Wittchen H-N (1996) Ecstasy-und Halluzinogengebrauch bei Jugendlichen. Gibt es eine Zunahme ? Verhaltenstherapie 6: 222–223CrossRefGoogle Scholar
  452. Schwarz CJ (1968) The complications of LSD: a review of the literature. J Nerv Ment Dis 146: 174–186CrossRefGoogle Scholar
  453. Sharma S, Moskowitz H (1972) Effect of marihuana on the visual autokinetic phenomenon. Percept Mot Skills 35: 891–894CrossRefGoogle Scholar
  454. Stefanis C, Dornbush R, Fink M (1977) Hashish-studies of long-term use. Raven, New YorkGoogle Scholar
  455. Shulgin AT, MacLean DE (1976) Illicit Synthesis of Phencyclidine (PCP) and several of its Analogs. Clin Toxicol 9 /4: 553–560CrossRefGoogle Scholar
  456. Sigrist T, Germann U, Sutter K (1998) Intoxikation mit Stechapfelgift ( Scopolamin ). Kriminalistik 3: 219–221Google Scholar
  457. Silverman J (1968) Shamans and acute schizophrenia. Am Anthropol 69: 21–31CrossRefGoogle Scholar
  458. Smith MV (1981) Psychedelic chemistry. Loompanics Unlimited Mason/USA (Nachdruck des 1973 in Rip Off Press erschienenen Werkes)Google Scholar
  459. Smith PB et al. (1994) The Pharmacological Activity of Anandamide, a Putative Endogenous Cannabinoid, in Mice. J of Pharmacol 270: 219–220Google Scholar
  460. Smith RN, Robinson K (1985) Body fluid levels of lysergide ( LSD ). Forensic Sci Int 28: 229–237Google Scholar
  461. Snyder SH (1967) STP: a new halluzinogenic drug. Science 158: 669–712CrossRefGoogle Scholar
  462. Soueif MI (1976) Differential association between chronic cannabis use and brain function deficits. Ann NY Acad Sci 282: 323–343CrossRefGoogle Scholar
  463. de Souza E, Battaglia G, Insel T (1990) Neurotoxic Effects of MDMA on Brain Serotonin Neurons: Evidence from Neurochemical and Radioligand Binding Studies. Ann NY Acad Sci 6: 682–698Google Scholar
  464. Soyka M et al. (1993) Zur Phänomenologie einer ketamininduzierten Psychose. Sucht 39 /5: 327–331Google Scholar
  465. Spanos LJ, Yamamoto BK (1989) Acute and subchronic effects of methylenedioxymethamphetamine ( MDMA) on locomotion and serotonin Syndrome behaviour in rat. Pharmacol Biochem Behav 32: 835–840Google Scholar
  466. Stafford P (1980) Enzyklopädie der psychedelischen Drogen. Volksverlag, LindenGoogle Scholar
  467. Stahl E et al. (1978) Rauschgiftpilze mit LSD ? Arch Krim 162 (1/2): 23Google Scholar
  468. Stanton MD, Mintz J, Franklin RM (1976) Drug flashbacks. II: Some additional findings. Int J Addict 11: 53–69Google Scholar
  469. Starks M (1979) Marijuana potency. And/Or Press, BerkeleyGoogle Scholar
  470. Steckel R (oJ) Bewußtseinserweiternde Drogen. Haschisch - Marihuana - LSD - Meskalin - STP(DOM) - Psilocybin - Ololiuqui. Edition VoltaireGoogle Scholar
  471. Stenchever MA, Kunysz TJ, Allen MA (1974) Chromosome breakage in users of marihuana. Am J Obstet Gynecol 118: 106–113Google Scholar
  472. Stoll WA (1947) Lysergsäureamid, ein Phantastikum aus der Mutterkorngruppe. Schweiz Arch Neurol Psychiatr 60: 279–323Google Scholar
  473. Stoll WA (1952) Recent investigations on ergot alkaloids. Fortschr Chem Org Naturst 9: 114–119Google Scholar
  474. Stosberg K, Lösch H (1987) Haschisch-Spätfolgen. Suchtreport 5: 13–16Google Scholar
  475. Stowe BB (1959) Occurence and metabolism of simple indoles in plants. Fortschr Chem Org Naturst 17: 248–252Google Scholar
  476. Stringaris MG (1972) Die Haschischsucht. Springer, Berlin Heidelberg New YorkCrossRefGoogle Scholar
  477. Stromberg VL (1954) The Isolation of bufotenin from Piptadenia peregrina. J Am Chem Soc 76: 170–171CrossRefGoogle Scholar
  478. Sullivan AT, Twitchett PJ, Fletcher SM, Moffat AC (1978) The fate of LSD in the body: forensic considerations. J Forensic Sci 18: 89–98CrossRefGoogle Scholar
  479. Svrcek M (1979) Der Kosmos-Pilzführer. Frank’sche Verlagsbuchhandlung, StuttgartGoogle Scholar
  480. Swatek R (1984) Marijuana use: Persistence and urinary elimination. J Substance Abuse Treatment 1: 265–270CrossRefGoogle Scholar
  481. Täschner K-L (1980) Haschisch für alle ? Hess Ärztebl 7 (Sonderdruck)Google Scholar
  482. Täschner K-L (1981) Das Haschischproblem aus klinischer Sicht. Dtsch Ärztebl 78: 126–129Google Scholar
  483. Täschner K-L (1983) Zur Psychopathologie und Differentialprognose sogenannter Cannabispsychosen. Fortschr Neurol Psychiatr 51: 235–248CrossRefGoogle Scholar
  484. Täschner K-L (1986) Das Cannabisproblem - Haschisch und seine Wirkungen. Deutscher Ärzte-Verlag, KölnGoogle Scholar
  485. Täschner K-L, Wanke K (1975) Zur Frage der toxischen Psychose am Beispiel der sog. LSD-Psychose. Fortschr Med 31: 1515–1518, 1542Google Scholar
  486. Täschner K-L, Frießen DH (1989) Verkehrstauglichkeit bei Rauschgiftkonsumenten unter besonderer Berücksichtigung des Cannabismißbrauchs. Suchtgefahren 35: 253–262 (Sonderdruck)Google Scholar
  487. Tarshis MS (1972) The LSD controversy - an overview. Thomas, Springfield/ IL Tashkin DP (1987) Marijuana-Bronchitis. Am Rev Resp Dis 135: 209Google Scholar
  488. Thomasius R et al. (1997) MDMA (“Ecstasy”)-Konsum - ein Überblick zu psychiatrischen und medizinischen Folgen. Fortschr Neurol Psychiatr 65: 49–61 (Sonderdruck)Google Scholar
  489. Tashkin DP, Simmons M, Clark V (1988) Effect of habitual smoking of marijuana alone and with tobacco on nonspecific airways hyperreacticity. J Psychoactive Drugs 20: 2125Google Scholar
  490. Taylor FM (1988) Marijuana as a potential respiratory tract carcinogen: a retrospective analysis of a community hospital population. South Med J 81: 1213–1216CrossRefGoogle Scholar
  491. Taylor WI (1966) Indole alkaloids, an introduction to the enamine chemistry of natural products. Pergamon, New YorkGoogle Scholar
  492. Teitelbaum DT, Wingeleth DC (1977) Diagnosis and management of recreational mescaline poising. J Anal Toxicol 1: 36–37Google Scholar
  493. Tennant FS, Groesbeck CJ (1972) Psychiatric effects of Hashish. Arch Gen Psychiatry 27: 133–136CrossRefGoogle Scholar
  494. Tennant FS, Preble M, Prendergast TJ, Ventry P (1971) Medical manifestations associated with Hashish. Jama 216: 1965–1969CrossRefGoogle Scholar
  495. Tenscher E, Lindenquist U (1994) Biogene Gifte. Gustav-FischerGoogle Scholar
  496. Teuchert-Noodt G, Bagorda F (2002) Drogen-induzierte Destabilisierung psycho-kognitiver Leistungen als Gefahr für den Straßenverkehr–Wie sich Ecstasy und andere Drogen in das Gehirn einschreiben, und die Frage nach den Chancen einer Therapie. Blutalkohol 39 (Suppl. 1): 21–31Google Scholar
  497. Thamm BG (1987 a) Alltagsdroge Haschisch. Suchtreport 1/4:2–7Google Scholar
  498. Thamm BG (1987 b) Synthetische Drogen. Suchtreport 1/3:52–54Google Scholar
  499. Thamm BG (1990) Pflanzen der Götter. Suchtreport 4 /3: 48–57Google Scholar
  500. Theale JD, Forman EF, King LJ (1975) The development of a radioimmunassay for cannabinoids in blood and in urine. J Pharm Pharmacol 27: 465–472CrossRefGoogle Scholar
  501. Thomas WR, Holt PG, Keast D (1974) Recovery of immune system after cigarette smoking. Nature 248: 358–359CrossRefGoogle Scholar
  502. Thomasius R (Hrsg.)(1998) Ecstasy-Wirkungen, Risiken, Interventionen. Ein Leitfaden für Klinik und Praxis. Enke, StuttgartGoogle Scholar
  503. Thomasius R (Hrsg.)(2000) Ecstasy. Eine Studie zu gesundheitlichen und psychosozialen Folgen des Missbrauchs. Wiss Verlagsges, StuttgartGoogle Scholar
  504. Thomasius R, Jarchow C (1997) “Ecstasy”: Psychotrope Effecte, Komplikationen, Folgewirkungen. Dtsch Ärztebl 94A:372–376 (Sonderdruck)Google Scholar
  505. Tong TG, Benowitz NL, Becker CE, Forni PJ, Boerner U (1975) Phencyclidine Poisoning. Jama 234 /5: 572–573CrossRefGoogle Scholar
  506. Tossmann HP (1997) Ecstasykonsummuster, Konsumkontexte und Komplikationen. Ergebnisse der Ecstasy-Infoline. Sucht 43: 121–129Google Scholar
  507. Treffert DA (1978) Marihuana use in schizophrenia: a clear hazard. Am J Psychiatry 135: 1213–1215Google Scholar
  508. Ungerleider JT et al. (1968) The “bad trip”–the etiology of the adverse LSD reaction. Am J Psychiatry 124: 1483–1490Google Scholar
  509. Vierth G (1967) Psycho-pathologische Syndrome nach Haschischgenuß. Mmw 1: 522–528Google Scholar
  510. Vogel R, Matthiessen W, Bruckner O, Alexander M (1981) Lungenkomplikationen bei Rauschgiftsucht. Prax Pneumol 35: 988–991Google Scholar
  511. Van Peteghen C, Heyndrickx A, Van Zelle W (1980) GLC-mass spectral determination of mescaline in plasma of rabbits after intravenous injection. J Pharm Sci 69: 118–120CrossRefGoogle Scholar
  512. Völger G (Hrsg.)(1982) Rausch und Realität, Drogen im Kulturvergleich, Bde 1–3. Rowolth, Reinbek (Materialienband zur Ausstellung des Rautenstrauch-Joest-Museums für Völkerkunde der Stadt Köln 1981, Teil 1 und 2)Google Scholar
  513. Wasson RG, Hofman A, Ruck CAP (1978) The road to Eleusis: Unveiling the secrets of the mysteries. Harcourt Brace Jovanovich, New YorkGoogle Scholar
  514. Wall ME, Perez-Reyes M (1981) The metabolism of delta-9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 21: 178s - 189sGoogle Scholar
  515. Wall ME, Sadler BM, Brine D et al. (1983) Metabolism, disposition, and kinetics of delta9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 34: 352–363CrossRefGoogle Scholar
  516. Waser P (1971) Pharmakologische Wirkungsspektren von Halluzinogenen. Bull Schweiz Akad Med Wiss 27: 39–57Google Scholar
  517. Wasson RG (1959) The hallucinogenic mushrooms of Mexiko. Academy of Science, New YorkGoogle Scholar
  518. Wasson RG (1962) The hallucinogenic mushrooms of Mexiko and psilocybin: a bibliography. Bot Mus Leafl Hary Univ 20: 20–73Google Scholar
  519. Wasson RG (1968) Soma. Divine mushroom of immortality. Harcourt Brace Jovanovich, New YorkGoogle Scholar
  520. Wasson VP, Wasson RG (1957) Mushrooms. Russia and history. Pantheon, New YorkGoogle Scholar
  521. Wax RH, Wax ML (1962) The magical world view. J Sci Study Rel 1: 179–188CrossRefGoogle Scholar
  522. Weidmann H, Taeschler M, Konzett H (1958) Zur Pharmakologie von Psilocybin, einem Wirkstoff aus Psilocybe mexicana Heim. Experentia 14: 378–379CrossRefGoogle Scholar
  523. Wells B (1974) Psychedelic drugs. Penguin, BaltimoreGoogle Scholar
  524. Whites SC, Brin SC, Janicki BW (1975) Mitogen-induced blastogenic responses of lymphocytes from marihuana smokers. Science 188: 71–72CrossRefGoogle Scholar
  525. Whiting JD, Manders WW (1982) Confirmation of Tetrahydrocannabinol Metabolite in Urine by Gas Chromatography. J Anal Toxicol 6: 49–52Google Scholar
  526. Widmann M, Agurell S, Ehrnbo M, Jones G (1974) Binding of (+)-A1-and–Al-tetrahydrocannabinols and 7-hydroxytetrahydrocannabinol in blood cells and plasma proteins in man. J Pharm Pharmacol 26: 914–916CrossRefGoogle Scholar
  527. Williams EG, Himmelsbach CK, Wikler A, Ruble D C, Lloyd BJ Jr (1964) Studies on marijuana and parahexyl compund. Public Health Rep 61: 1059–1084Google Scholar
  528. Williams PL, Moffat AC (1980) Identification in human urine of delta-9-tetrahydrocannabino1–11-oc acid glucuronide: a tetrahydrocannabinol metabolite. J Pharm Pharmacol 32: 445–448CrossRefGoogle Scholar
  529. Winterfeldt E (1971) Neuere Aspekte in der Chemie der Indolalkaloide. Chimia 25: 394–396Google Scholar
  530. Winterfeldt E (1974) Stereoselektive Totalsynthese von Indolalkaloiden. Fortschr Chem Org Naturst 31: 469–472Google Scholar
  531. Woggon B (1974) Haschisch - Konsum und Wirkung. Springer, Berlin Heidelberg New YorkGoogle Scholar
  532. Yago KB, Pitts FN Jr, Burgoyne RW et al. (1981) The urban epidemie of phencyclidine ( PCP) use. J Clin Psychiatry 42: 193–196Google Scholar
  533. Yesavage JA et al. (1985) Carry-over effects of marihuana intoxication on aircraft pilot performance. Am J Psychiatry 142: 1325–1329Google Scholar
  534. Zimmermann AM, Ray AY (1980) Influence of cannabinoids on somatic cells in vivo. Pharmacol 21: 277–287CrossRefGoogle Scholar
  535. Zellweger H, McDonald JS, Abbo G (1967) Is isoergicacid diethylamide a teratogen ? Lancet 7525: 1066–1068CrossRefGoogle Scholar
  536. Zimmermann S, Zimmermann AM, Cameron IL, Laurence HL (1977) Delta-9-tetrahydrocannabinol, cannabidiol and cannabinol effects on the immune response of mice. Pharmacol 15: 10–23CrossRefGoogle Scholar
  537. Zinck R, Möller D (Hrsg.)(1998) Designer-Drogen vom Amphetamin-Typ “Ecstasy”. Abbott, WiesbadenGoogle Scholar
  538. Zingg C, Bovens M (2000) “Ecstasy”-Tabletten und deren kriminalpolizeiliches Auswertungspotenzial. Kriminalistik 12: 833–838Google Scholar
  539. Zuger V (1974) Eine neue Form von Haschisch. Haschisch-Öl. Kriminalistik 18 /3: 129Google Scholar
  540. Zschockelt A (1986) Die “nicht geringe Menge” Cannabis–Problematik der THC-Bestimmung. Mdr 6: 457–459Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • Thomas Geschwinde
    • 1
  1. 1.HanauDeutschland

Personalised recommendations